Literature DB >> 35278812

Plasma secretome analyses identify IL-8 and nitrites as predictors of poor prognosis in nasopharyngeal carcinoma patients.

Ahmed Amine Zergoun1, Kyle S Draleau2, Faycal Chettibi3, Chafia Touil-Boukoffa1, Djamel Djennaoui3, Taha Merghoub4, Mehdi Bourouba5.   

Abstract

Predicting tumor recurrence and death in patients with nasopharyngeal carcinoma (NPC) remains to date challenging. We here analyzed the plasmatic secretomes of NPC untreated and relapsing patients, and explored possible correlations with the clinical and pathological features and survival characteristics of the corresponding patient cohorts, with the aim of identifying novel prognostic biomarkers. This study included 27 controls, 45 untreated NPC and 11 relapsed patients. A set of 14 plasma cytokines were analyzed using Millipore multiplex assay. Nitrites were assessed by Griess method. A comparative analysis of each groups' secretome showed upregulation of IL-8, IL-12p70, IL-10 and IP-10 in untreated patients, and of IL-6, IL-10, MCP-1 and IP-10 in relapsing patients. Nitrites significantly correlated with IL-8 during relapse. Secretomes' network analyses revealed prevalence of high correlations between IL8/IL-17A and IFN-γ/IL12p70 in the control group, between TNF-α/IL-8/IL-6, TNF-α/VEGF/IFN-γ and IL-10/MCP-1 in the untreated group, and between IL-8/IL-6/IL-10, TNF-α/IL-8/IL-6, IL12-p70/VEGF/IL-10/IFN-γ, IL-6/IL-10/IFN-γ and IL-8/IP-10 in the relapse group. IL-12p70, IP-10 and MCP-1 levels respectively associated with gender, age and node metastasis respectively. Recurrence-free survival (RFS) analysis showed that patients presenting High IL-8/Low NO immunological scores presented a combined 80% probability of relapse/death after 53 months (combined log-rank test p = 0.0034; individual p = 0.012 and p = 0.016). Multivariate Cox hazard regression analysis revealed that IL-8 (HR = 7.451; 95% CI [2.398-23.152]; p = 0.001) and treatment type (HR = 0.232; 95% CI 0.072-0.749; p = 0.015) were independent prognostic factors. C&RT decision tree analysis showed that High IL-8/Low NO immunological scores predicted treatment failure in 50% cases starting the 36th month of follow-up (AUC = 1) for all of the studied cases and in 57% cases for patients receiving chemotherapy alone (AUC = 1). Altogether, our results showed that NPC development is accompanied with cytokines deregulation to form specific interaction networks at time of diagnosis and relapse, and demonstrate that High IL-8/Low NO signature may constitute a predictor of poor prognosis which may be useful to improve risk stratification and therapy failure management.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytokine; IL-8; Nasopharyngeal carcinoma; Nitric oxide; Prognosis

Mesh:

Substances:

Year:  2022        PMID: 35278812      PMCID: PMC9375845          DOI: 10.1016/j.cyto.2022.155852

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.926


  62 in total

1.  Serum Nitric Oxide as a Predictive Biomarker for Bevacizumab in Non-small Cell Lung Cancer Patients.

Authors:  Satoshi Muto; Hironori Takagi; Yuki Owada; Takuya Inoue; Yuzuru Watanabe; Takumi Yamaura; Mitsuro Fukuhara; Naoyuki Okabe; Yuki Matsumura; Takeo Hasegawa; Jun Osugi; Mika Hoshino; Mitsunori Higuchi; Yutaka Shio; Hiroyuki Suzuki
Journal:  Anticancer Res       Date:  2017-06       Impact factor: 2.480

Review 2.  Cancer immunoediting from immune surveillance to immune escape.

Authors:  Ryungsa Kim; Manabu Emi; Kazuaki Tanabe
Journal:  Immunology       Date:  2007-03-26       Impact factor: 7.397

3.  TNFα antagonization alters NOS2 dependent nasopharyngeal carcinoma tumor growth.

Authors:  Mehdi Bourouba; Ahmed-Amine Zergoun; Joseph S Maffei; Dalia Chila; Djamel Djennaoui; Fatima Asselah; Zine-Charef Amir-Tidadini; Chafia Touil-Boukoffa; Muhammad H Zaman
Journal:  Cytokine       Date:  2015-04-23       Impact factor: 3.861

4.  Epstein-Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-kappa B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line.

Authors:  Qingchun Ren; Hiroshi Sato; Shigeyuki Murono; Mitsuru Furukawa; Tomokazu Yoshizaki
Journal:  Laryngoscope       Date:  2004-05       Impact factor: 3.325

Review 5.  Chronic inflammation and cytokines in the tumor microenvironment.

Authors:  Glauben Landskron; Marjorie De la Fuente; Peti Thuwajit; Chanitra Thuwajit; Marcela A Hermoso
Journal:  J Immunol Res       Date:  2014-05-13       Impact factor: 4.818

6.  CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.

Authors:  Holger Bronger; Judith Singer; Claudia Windmüller; Ute Reuning; Daniela Zech; Claire Delbridge; Julia Dorn; Marion Kiechle; Barbara Schmalfeldt; Manfred Schmitt; Stefanie Avril
Journal:  Br J Cancer       Date:  2016-08-04       Impact factor: 7.640

7.  Selected serum cytokines and nitric oxide as potential multi-marker biosignature panels for Parkinson disease of varying durations: a case-control study.

Authors:  Dilini Rathnayake; Thashi Chang; Preethi Udagama
Journal:  BMC Neurol       Date:  2019-04-06       Impact factor: 2.474

8.  Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma.

Authors:  Rosalinda Arends; Xiang Guo; Paul G Baverel; Ignacio González-García; James Xie; Nassim Morsli; Alejandro Yovine; Lorin K Roskos
Journal:  Oncoimmunology       Date:  2021-03-17       Impact factor: 8.110

9.  IP-10/CXCL10 attracts regulatory T cells: Implication for pancreatic cancer.

Authors:  Serena Lunardi; Su Yin Lim; Ruth J Muschel; Thomas B Brunner
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

10.  IP-10 (CXCL10) Can Trigger Emergence of Dormant Breast Cancer Cells in a Metastatic Liver Microenvironment.

Authors:  Amanda M Clark; Haley L Heusey; Linda G Griffith; Douglas A Lauffenburger; Alan Wells
Journal:  Front Oncol       Date:  2021-05-27       Impact factor: 5.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.